바인 테라퓨틱스(VYNE) 주가 전망 및 기업 분석 - PER·배당·실적·목표주가·RSI·MACD

VYNE

VYNE Therapeutics Inc

7월 27일 4:00 PM ET (한국 7/28 05:00)

$28.56

+3.11 ▲ +12.22%

바인 테라퓨틱스(VYNE) is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.

시가총액

$25M

스몰캡

P/E

배당수익률

3522.58%

52주 위치

56%

저점 +261% · 고점 -37%

애널리스트

매수

C+

Fundamental health

vs. 미분류 초소형주· based on 3 axes

수익성

산출 불가 (적자)

성장

Top 53%

밸류에이션

Top 48%

재무 안정

Top 38%

Index ⓘ	-	P/E ⓘ	-	EPS (ttm) ⓘ	-26.68	Insider Own ⓘ	19.55%	Shs Outstand ⓘ	0.9M	Perf Week ⓘ	25.33%
Market Cap ⓘ	0.02B	Forward P/E ⓘ	-	EPS next Y ⓘ	-	Insider Trans ⓘ	-	Shs Float ⓘ	0.7M	Perf Month ⓘ	55.35%
Enterprise Value ⓘ	-0.00B	PEG ⓘ	-	EPS next Q ⓘ	-	Inst Own ⓘ	30.73%	Short Float ⓘ	0.53%	Perf Quarter ⓘ	56.94%
Income ⓘ	-0.02B	P/S ⓘ	54.56	EPS this Y ⓘ	-	Inst Trans ⓘ	13.74%	Short Ratio ⓘ	0.14	Perf Half Y ⓘ	74.4%
Sales ⓘ	0.00B	P/B ⓘ	0.77	EPS next 5Y ⓘ	-	ROA ⓘ	-52.78%	Short Interest ⓘ	0.00M	Perf YTD ⓘ	74.52%
Book/sh ⓘ	36.93	P/C ⓘ	0.98	EPS past 3/5Y ⓘ	62.06% 66.27%	ROE ⓘ	-63.16%	52W High ⓘ	-36.53% ($44.99)	Perf Year ⓘ	-30.66%
Cash/sh ⓘ	29	P/FCF ⓘ	-	Sales past 3/5Y ⓘ	6.12% -51.39%	ROIC ⓘ	-87.09%	52W Low ⓘ	260.93% ($7.91)	Perf 3Y ⓘ	-73.07%
Dividend Est. ⓘ	$1006.05 (3522.58%)	EV/EBITDA ⓘ	-	EPS Y/Y TTM ⓘ	46.11%	Gross Margin ⓘ	94.93%	Volatility(W/M) ⓘ	12.48% 7.48%	Perf 5Y ⓘ	-97.92%
Dividend TTM ⓘ	1006.05	EV/Sales ⓘ	-0.84	Sales Y/Y TTM ⓘ	-24.96%	Oper. Margin ⓘ	-5367.62%	ATR (14) ⓘ	1.89	Perf 10Y ⓘ	-
Dividend Ex-Date ⓘ	2026/7/24	Quick Ratio ⓘ	20.86	EPS Q/Q ⓘ	58.47%	Profit Margin ⓘ	-4726.21%	RSI (14) ⓘ	84.01	Recom ⓘ	2.33
Dividend Gr. 3/5Y ⓘ	-	Current Ratio ⓘ	20.86	Sales Q/Q ⓘ	-57.43%	SMA20 ⓘ	34.57% ($21.22)	Beta ⓘ	1.95	Target Price ⓘ	$100
Payout ⓘ	-	Debt/Eq ⓘ	0	Earnings ⓘ	-	SMA50 ⓘ	45.01% ($19.7)	Rel Volume ⓘ	3.59	Prev Close ⓘ	$25.45
Employees ⓘ	10	LT Debt/Eq ⓘ	0	EPS/Sales Surpr. ⓘ	1.92% 35.2%	SMA200 ⓘ	78.5% ($16)	Avg Volume(3M) ⓘ	0.03M	Price ⓘ	$28.56
IPO ⓘ	2018/1/25	Option/Short ⓘ	No/Yes			Trades ⓘ	1851	Volume ⓘ	93,800	Change ⓘ	12.22%

Quarterly earnings trend SEC filings · USD

23.12*

24.3

24.6

24.9

24.12*

25.3

25.6

26.3

Revenue Net income 최근 분기: 매출 $0M (YoY -57%) · 순이익 $-4M (YoY +58%)

* Q4 figures are derived from the annual filing (10-K) · loss-making quarters are underlined in red

📊 VYNE Therapeutics Inc (VYNE) Investment Analysis

What kind of company is VYNE Therapeutics Inc?

바인 테라퓨틱스(VYNE)

Healthcare · Biotechnology

Small-Cap — Low Volume, High Volatility

💊 VYNE Therapeutics () is a clinical-stage small biotech developing treatments for immune and inflammatory diseases based on its BET protein inhibitor (InhiBET™) platform. The company holds both oral and topical drug candidates targeting a range of indications, including psoriasis, vitiligo, and myelofibrosis. With no marketed flagship product yet, its corporate value is heavily dependent on the clinical outcomes of its pipeline.

Learn more about VYNE Therapeutics Inc →

Market Cap

$0.0B

Approx. KRW 0.0 trillion

⚖️ 0% of Samsung Electronics

Market Cap Rank5196

Employees10people

IPO2018/01/25

Current Price$28.56 ≈ 39,127원

NASD · USA

Key Events

⏰ Upcoming events

🔔 Earnings release

The next release date has not been announced yet.

🎯 Ex-dividend date

No scheduled dividends

📜 Recent events

🎯 Ex-div 2026년 7월 24일 (금)

🎯 Ex-div 2026년 7월 22일 (수)

🔔 Earnings release 2025년 11월 6일 (목) · 장 시작 전 EPS +1.9% 매출 +35.2%

Is it profitable?

Financially sound but profitability is low

Losses or thin margins — early-stage growth or weakening competitiveness

Profitability — How efficiently it makes money

Operating Margin

Profit kept from selling products and services (higher is better)

-5367.6%

✓ 적자

💡 적자 상태 — 수익을 내지 못하고 있습니다

Net Margin

Share of revenue left after taxes and interest are paid

-4726.2%

✓ 적자

💡 적자 상태 — 수익을 내지 못하고 있습니다

Gross Margin

Profit after subtracting raw-material costs only (signals product competitiveness)

94.9%

✓ 우수

My positionTop 25%

Low range Average High range

Biotechnology 초소형주 Median 53.4% · Top 12%

💡 제조업 30%, IT/소프트웨어 50% 이상이면 우수 (업종별 편차 큼)

ROE

Annual return earned on shareholders' equity (15%+ is strong)

-63.2%

✓ 적자

💡 적자 상태 — 수익을 내지 못하고 있습니다

ROA

Annual earnings relative to total company assets

-52.8%

✓ 적자

💡 적자 상태 — 수익을 내지 못하고 있습니다

ROIC

Return generated per dollar invested in the business

-87.1%

✓ 적자

💡 적자 상태 — 수익을 내지 못하고 있습니다

Financial health — Debt & liquidity burden

Debt-to-Equity (D/E)

Debt relative to equity (lower is healthier)

0.00

✓ Very low debt

My positionTop 5%

Low range Average High range

Biotechnology Median 0.05

💡 일반적으로 1.0 이하면 건전, 1.5까지는 무난 (금융·유틸·REIT는 구조적으로 높음)

Current Ratio

Liquid assets available to cover liabilities due within a year

20.86

✓ 우수

My positionTop 25%

Low range Average High range

Biotechnology Median 5.75

💡 1.5~3.0 적정, 1.0 미만이면 단기 유동성 주의

Quick Ratio

Liquid assets excluding inventory, available for immediate use

20.86

✓ 우수

My positionTop 25%

Low range Average High range

Biotechnology Median 5.47

💡 1.0 이상이면 안전, 0.5 미만이면 주의

* Ratings reflect relative position vs. peer-group distribution (same sector & size) plus absolute guards (loss & risk thresholds).

What's the outlook?

Mixed Outlook

Positive and negative signals are mixed

애널리스트 목표가

$100.00

현재가 대비 +250.1%

💡 12개월 이내 도달을 전망하는 애널리스트 컨센서스 평균

⚠ 이 데이터는 애널리스트 추정치이며 실제 결과와 다를 수 있습니다. 투자 결정은 추가 검토와 함께 하세요.

Did earnings meet expectations?

High Earnings Volatility

Frequently misses analyst estimates

예상 상회

예상 부합

예상 하회

상회 비율

-30.8%

평균 서프라이즈

2025.11.06

하회

실적 $-0.17 · 예상 $-0.13 -30.8%

💡 예상보다 높은 실적을 자주 내는 기업은 실적 신뢰도가 높다고 평가됩니다. 단, 애널리스트 기대치가 낮게 설정되었을 수도 있으니 절대 수치도 함께 봐야 합니다.

Is it growing?

Average Growth

Mid-range within the industry

Declining Growth EPS or revenue is declining — check for structural issues or economic sensitivity

📊 How much has it grown? (actual results)

Past 3-Year EPS

Actual average annual EPS growth over the past 3 years

+62.1%

우수

My positionTop 25%

Low range Average High range

미분류 초소형주 Median 25.4% · Top 20%

Past 5-Year EPS

Actual average annual EPS growth over the past 5 years

+66.3%

우수

My positionTop 5%

Low range Average High range

미분류 초소형주 Median 14.6% · Top 4%

Past 5-Year Revenue

How much revenue grew over the past 5 years

-51.4%

매우 부진

My positionBottom 5%

Low range Average High range

미분류 초소형주 Median 2.8% · Bottom tier

⚡ Short-term momentum

QoQ Revenue

Revenue change from the previous quarter (short-term momentum)

-57.4%

부진

My positionBottom 25%

Low range Average High range

미분류 초소형주 Median -2.6% · Bottom 12%

* Forecast values are analyst consensus estimates. Ratings are determined by relative position vs. peer group of the same growth style and size.

New to investing terms? Look it up in the financial dictionary →

Has the stock risen over the long term?

Long-term weakness — -166%p below the market

VYNE -97.9% · S&P 500 +68.3%

Excess return vs. market (price-based, ex-dividends)

5-year basis

vs S&P 500

-166.3%p

Significantly behind the market

vs Health Care (XLV)

-122.4%p

Significantly behind the sector average

1-year basis

vs S&P 500

-46.7%p

Significantly behind the market

vs Health Care (XLV)

-50.4%p

Significantly behind the sector average

Rank among peers

5-year return Lower-Mid (lower 38%) Based on 245 peers

1-year return Upper-Mid (39%) Based on 315 peers

Current position within 52-week range

Low (-260.9%p) High (-36.5%p)

Current price is 260.9% above the 52-week low and 36.5% below the 52-week high

Recent risk (last 120 trading days)

Max drawdown

-44.6%

Annualized volatility

593.4%

Technical Indicators

Bollinger Bands · MACD · RSI · Stochastics · Ichimoku 5-line · recent 136-day series

Price · Bollinger Bands · Ichimoku Cloud

close
BB Upper
BB Mid
BB Lower
Tenkan
Kijun
Cloud (SpanA/B)

Bollinger Bands are upper and lower channels showing the closing price range (20 days · 2σ). Touching the upper band = overheated; touching the lower band = oversold. Ichimoku Cloud shows trend direction and strength through colored areas. Prices above the cloud indicate an uptrend; prices below indicate a downtrend. About Bollinger Bands →

⚠️

Current diagnosis · 2026-07-27

Overbought zone — short-term pullback possible

Current price $28.56 broke above the upper band ($14.25). Stronger buying than average, but signals short-term overheating. Above the Ichimoku cloud (bullish).

MACD (12 · 26 · 9) Expand ▼

An indicator that uses the difference between the short-term EMA (12) and long-term EMA (26) to identify trend reversals. When MACD rises above the Signal line, it is a buy signal (golden cross); when it falls below, it is a sell signal (death cross). About MACD →

✨

Current diagnosis · 2026-07-27

Golden cross — bullish reversal signal

MACD(2.247) crossed above Signal(0.474). Trend reversal possible; read as a buy entry point.

RSI(14) · Stochastics %K(14) Expand ▼

RSI measures short-term buying and selling pressure on a scale of 0–100. 30 or below = oversold (a rebound may be possible); 70 or above = overbought (a pullback may be possible). Stoch %K similarly measures short-term momentum strength. RSI · Learn more about Stochastics →

⚠️

Current diagnosis · 2026-07-27

Overbought zone — short-term pullback possible

RSI 98.5 (above 70). Buying pressure is excessive, and profit-taking may emerge. Stoch %K is also 100.0.

※ "Current diagnosis" is an automated interpretation based on standard thresholds and is for reference only. Make your own comprehensive judgment before trading.

Is it attractive at this price?

In line with the industry average

Cheap on Vs. Assets, Pricey on Vs. Sales

💡 How to read this — Compare against peers in the same industry to see what the price is cheap or expensive relative to. Example: cheap vs. earnings = stock price is low relative to what the company earns; expensive vs. assets = stock price is high relative to assets on the balance sheet.

🏢 Vs. Assets Cheap

🧾 Vs. Sales Pricey

🏢 Vs. Assets

PBR Price-to-Book Ratio

Price vs. the company's asset value — below 1 trades cheaper than assets

0.77x

✓ Cheap

My positionMid-range

Low range Average High range

Biotechnology 초소형주 median 1.35x · Around the industry average

💡 PBR 1 미만이면 청산가치 이하 (금융·제조업에서 특히 의미, IT는 낮은 비중)

🧾 Vs. Sales

PSR Price-to-Sales Ratio

Market cap vs. revenue — lower is cheaper relative to sales

54.56x

✓ Pricey

My positionBottom 25%

Low range Average High range

Biotechnology 초소형주 median 11.24x · Bottom 25% — expensive within the industry

💡 PSR 2 이하 저평가, 10 초과면 고평가 (고성장 기업일 때만 정당화)

Analyst target price (reference)

$100.00 vs. current price +250.1%

* Valuation is the stock's relative position within the industry peer group (same sector and market-cap range). Even when valuation looks attractive, check the 'Profitability' and 'Growth' sections too.

As of: Recent snapshot · Peer group: Biotechnology 초소형주

Who owns it?

Ownership flow is positive

Institutional net buying +13.7% · Short interest light 0.5%

📈 Recent trading flow (6 months)

🧑‍💼 Insiders (executives & directors)

0.0%

Insiders little change

🏦 Institutions (funds & investors)

+13.7%

Institutions large net buying

💡 Net change over the past 6 months. Shows how much insiders and institutions increased or reduced their holdings, in %.

👥 Holdings composition

🏦 Institutions 30.7%

Moderate institutional participation

Healthcare 초소형주 Median 14.2%

🧑‍💼 Insiders 19.6%

Founder/management large holders (strong skin-in-the-game)

Healthcare 초소형주 Median 16.1%

👤 Retail investors (estimated) 49.7%

Everyone excluding institutions and insiders

Institutions Insiders Retail (est.)

📉 Short-selling metrics

Short ratio

0.5%

Low — limited short-side pressure

Healthcare 초소형주 Median 3.9%

Past 89 days Little change

Short interest days to cover

0.1 days

Days needed to close short positions using average trading volume

🧮 Share count

Total shares outstanding 0.9M주

Float (tradable shares) 0.7M주

* Insider/institutional flows are based on net changes over the past 6 months. Trend is cumulative over the past 89 days.

ETFs holding VYNE

ETFs with the highest weightings · 1 total shown

VXF

Vanguard Extended Market Index ETF

0.00%

$30.4B

* Based on official quarterly filings. Latest disclosure; actual current weights may differ.

How much does it pay in dividends?

고배당주 — 연 3522.58% 배당

Dividend Yield

3522.58%

Industry average 1.23%

Dividend Per Share

$1006.05

Annualized

Payout Ratio

Share of net income paid as dividends

5-Year Growth

Annualized dividend growth

💰 내가 100만원 투자한다면

연간 배당금 (세후) 2994.2만원

5년 누적 (세후) 14971.0만원

* 환율 1,370원, 세금 15% 반영. 5년 누적은 배당 성장률 연 0% 가정.

Compare Industry Peers

💡 vs. sector average ▲ Favorable / ▼ Unfavorable (Lower PER and PBR are better; higher ROE and dividend yield are better)

Sorted by market cap, largest first

Stock	Market Cap	PER	PBR	ROE	Dividend Yield	Change
VYNE This Stock	$24.6M	-	0.8 ▲	-63.16% ▼	3522.58% ▲	+12.2%
LLY	$1.13T	43.1 ▼	36.2 ▼	107.64% ▲	0.58% ▼	+0.1%
JNJ	$640.9B	30.8 ▼	7.5 ▼	25.74% ▲	2.02% ▲	+1.0%
ABBV	$453.9B	126.7 ▼	-	15221.82% ▲	2.67% ▲	-0.9%
UNH	$379.3B	26.9 ▼	3.9 ▼	12.49% ▲	2.16% ▲	-0.7%
MRK	$323.0B	36.8 ▼	7.0 ▼	18.97% ▲	2.5% ▲	-0.2%
Sector Avg	-	26.1	2.7	-48.83%	1.23%	-

FAQ

What kind of company is 바인 테라퓨틱스(VYNE)?

바인 테라퓨틱스(VYNE) belongs to the Healthcare sector and operates in the Biotechnology industry.

What is the market cap of VYNE?

The market cap of VYNE is approximately $25M, ranking 5,196 within its sector.

Does VYNE pay dividends?

VYNE has a dividend yield of approximately 3522.58%, with an annual dividend of $1006.05.

What is the 52-week high and low for VYNE?

VYNE has recorded a 52-week high of $44.99 and a low of $7.91.

면책조항: 본 콘텐츠는 참고 자료이며 투자 권유가 아닙니다. 모든 투자의 책임은 투자자 본인에게 있습니다.